Belotecan has a significant effect on intracerebral glioma growth, with animals having significantly smaller tumors than those in the control group[3].
In Vitro
Belotecan exerts a significant cytotoxic effect on YD-8, YD-9 and YD-38 cells in a time- and dose-dependent manner with IC50 values of 2.4, 0.18 and 0.05 μg/mL at 72 h following treatment. Belotecan induces apoptosis in these cell lines. Belotecan induces G2/M phase arrest in oral squamous cell cancer cells[1]. Belotecan shows a significant anticancer effect on glioma cells, with IC50 values of 9.07 nM for LN229, 14.57 nM for U251 MG, 29.13 nM for U343 MG, and 84.66 nM for U87 MG[2].
Kinase Assay
Cell Assay
The cells are treated with different concentrations (0.01, 0.1, 0.5, 1, 5 and 10 μg/mL) of belotecan for 24, 48 and 72 h. Control samples of each cell line are treated with medium only. Cell viability is measured using the MTS assay[1].
Animal Administration
Mice: Nude mice with established U87MG glioma are treated with a dose of belotecan of 0 mg/kg (control group, injection with saline), 40 mg/kg (group A) or 60 mg/kg (group B). Thereafter, the dose is repeated once every 4 days for a total of four doses. Tumor volume is measured histologically and apoptosis is detected[1].
References
[1]. Kim YK, et al. Anticancer effects of CKD-602 (Camtobell®) via G2/M phase arrest in oral squamous cell carcinoma cell lines. Oncol Lett. 2015 Jan;9(1):136-142.
[2]. Kim YY, et al. CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. Oncol Rep. 2009 Jun;21(6):1413-9.
[3]. Kim CY, et al. Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model. J Clin Neurosci. 2012 Feb;19(2):301-5.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.